Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALIA-1758 · 1 trial · 1 indication
Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Single Ascending Dose (SAD) cohorts |
| Placebo | PLACEBO_COMPARATOR | Single Ascending Dose (SAD) cohorts |
| Name | Type | Description |
|---|---|---|
| ALIA-1758 | DRUG | Intravenous or subcutaneous doses |
| Placebo | OTHER | Intravenous or subcutaneous doses |
Key Inclusion Criteria: * Participants must understand the nature of the trial and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any trial-related procedures. * Healthy as determined by the Investigator, based on a medical evaluati...
Top 20 of 30 competitors
ALIA-1758 is an investigational small molecule being developed by AbbVie Inc. (ticker ABBV) for Alzheimer disease. It is in Phase 1 clinical development and has been studied in a single completed Phase 1 trial. It is not approved for any indication.
ALIA-1758 is being developed for Alzheimer disease. It is an investigational therapy and has not been approved for any use. The only clinical trial of ALIA-1758 completed to date enrolled healthy participants, not patients with Alzheimer disease.
ALIA-1758 targets 3pE-Aβ, a modified form of amyloid beta. The target class is an antibody. By binding 3pE-Aβ, the drug is designed to act on a specific amyloid species implicated in Alzheimer disease pathology.
ALIA-1758 is being developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie is the sponsor of the Phase 1 trial of ALIA-1758 conducted in the United States.
ALIA-1758 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
ALIA-1758 has been evaluated in one completed Phase 1 trial, NCT06406348, titled A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants. The trial enrolled 53 participants in the United States and was randomized, double-blind, and placebo-controlled.